目的 探讨药品监管对制药产业发展的影响及其机制。方法 基于1996~2016 年间中国制药产业数据,以药品监管强度为自变量,医药制造业利润率为因变量,研发创新和企业投资为中介变量,进行多元线性回归。结果 药品监管强度与利润率为显著正相关,研发创新起到显著的中介作用。结论 药品监管刺激了研发投入,促进了技术创新,技术创新的成果会增加企业绩效,而技术创新带来的企业绩效增加,完全弥补了规制成本所导致的企业绩效降低,结果增加了总的绩效。
Abstract
OBJECTIVE To study the impact and its mechanism of pharmaceutical regulation on the firm performance. METHODS To make the multiple regression analysis with the pharmaceutical regulation intensity as independent variable, profit rate as dependent variable, R&D innovation and firm investment as intervening variable, based on the pharmaceutical industry data of China. RESULTS The relationship between the pharmaceutical regulation intensity and profit rate is significantly positive correlation, for which the R&D innocation plays a role of mediation. CONCLUSION Pharmaceutical regulation stimulates the R&D revenue and enhances technical innovation, and thus the innovation achievement enhances the firm performance. The increase of firm performance brought by innovation compensates the drop by regulation cost.
关键词
药品监管 /
技术创新 /
企业绩效 /
制度基础观。
{{custom_keyword}} /
Key words
pharmaceutical regulation /
technical innovation /
firm performance /
institution based view
{{custom_keyword}} /
中图分类号：
R951
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] PORTERM E, LINDEC. Towarda new conception of the environmentcompetitiveness relationship . J Econ Persp, 1995,(4):97-118.
[2] PENG M W. Business strategies in transition economies. Thousand Oaks, CA:Sage, 2000.
[3] PENG M W. Towards an institutional-based view of business strategy. Asia Pac J Man, 2002, (19):251-267..
[4] GRABOWSKI H G, VERNON J M. Consumer protection regulation in ethical drugs. Am Econ Rev, 1977, (1):359- 364.
[5] THOMAS L G. Regulation and firm size:FDA impacts on innovation. RAND J Econ,1990, (4):497- 517.
[6] XUE L, GUO W, QIAO X. A study on social regulation amid the reform of streamlining administration and delegating government powers-taking China′s drug review regulation as atypical case. J Part Sch Cent Com CPC(中共中央党校党报), 2016, 20(4):34-43.
[7] YANG S, WANG G P, HUANG G, et al. A study on evaluation index system of the pharmaceutical regulationcapability of China. Chin Pharm J(中国药学杂志), 2014, 47(14) :1175-1177.
[8] WALTER L W, UGELOW J . Environmental policies in developing countries. Ambio, 1979, 8(2/3):102-109.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(1142 KB)
